doi: 10.1016/j.bcp.2023.115446 67 WangTCaiBDingMSuZLiuYShenL
Effects of GLP-1 RAs on Promoting Somatostatin Release and Inhibiting Glucagon Secretion The effects of GLP-1 RAs on the release of somatostatin and the inhibition of glucagon secretion are complex and multifaceted
Issue: Ophthalmologist unfamiliar or disapproving Common scenario: Most conventional ophthalmologists unfamiliar with peptide research, view as unproven experimental treatment, may discourage use out of caution or lack of knowledge
Depending on the needs of the study, prepared solutions may be maintained under refrigerated conditions for short-term use or frozen for longer-term laboratory storage, with aliquoting commonly used to help maintain sample integrity during repeated use
Generic semaglutide is expected to be developed to meet regulatory standards comparable to existing formulations. Demand for GLP-1 medications has increased significantly in recent years, which has contributed to supply pressures and pricing concerns in some markets, including the United States
